Autologous platelet-rich plasma (PRP) has been suggested to be effective for wound healing. However, clinical evidence for its use in patients with diabetic ulcer remains inconsistent. The aim of this systematic review and meta-analysis was to evaluate the efficacy and safety of PRP in patients with diabetic ulcer.
Recent Advances:
Relevant randomized controlled trials (RCTs) were identified via systematic search of PubMed, MEDLINE, EMBASE, the Cochrane Library, and Web of Knowledge databases. Results were pooled using a random-effects model. The primary outcome of the study was the healing rate of ulcers in patients with PRP, when compared with controls. Secondary outcomes included the percentage of ulcer area reduction, recurrence rate, and amputation rate.
Critical Issues:
Eight RCTs that involved 431 participants were included. Compared with controls, PRP was associated with a significantly increased ratio of complete ulcer healing (odds ratio [OR] = 3.77, 95% confidence interval [CI] = 1.91–7.45, I2= 42.2%) and reduced areas of ulcers (standard mean difference = 0.86, 95% CI = 0.27–1.45, I2= 0.0%). No differences were observed between patients allocated to PRP or controls, in terms of the outcomes of recurrence rate (OR = 3.32, 95% CI = 0.41–27.18, I2= 66.3%) or amputation rate (OR = 0.15, 95% CI = 0.15–1.28). The results of the trial sequence analyses revealed that the cumulative Z-curve crossed both the traditional boundary (p = 0.05) and trial sequential monitoring boundary.
Future Directions:
Our findings suggest that PRP may improve ulcer healing without significant adverse effects for patients with diabetic ulcers.
Get full access to this article
View all access options for this article.
References
1.
GuariguataL, WhitingDR, HambletonI, BeagleyJ, LinnenkampU, ShawJE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract, 2014; 103:137–149.
2.
TzengYS, DengSC, WangCH, TsaiJC, ChenTM, BurnoufT. Treatment of nonhealing diabetic lower extremity ulcers with skin graft and autologous platelet gel: a case series. Biomed Res Int, 2013; 2013:837620.
3.
GuestJF, FullerGW, VowdenP. Diabetic foot ulcer management in clinical practice in the UK: costs and outcomes. Int Wound J, 2018; 15:43–52.
BennettSP, GriffithsGD, SchorAM, LeeseGP, SchorSL. Growth factors in the treatment of diabetic foot ulcers. Br J Surg, 2003; 90:133–146.
6.
HoudekMT, WylesCC, StalboergerPG, TerzicA, BehfarA, MoranSL. Collagen and fractionated platelet-rich plasma scaffold for dermal regeneration. Plast Reconstr Surg, 2016; 137:1498–1506.
7.
ApelqvistJ, BakkerK, van HoutumWH, Nabuurs-FranssenMH, SchaperNC. International consensus and practical guidelines on the management and the prevention of the diabetic foot. International Working Group on the Diabetic Foot. Diabetes Metab Res Rev, 2000; 16Suppl 1:S84–S92.
8.
KakudoN, KushidaS, KusumotoK. Platelet-rich plasma: the importance of platelet separation and concentration. Plast Reconstr Surg, 2009; 123:1135–1136.
9.
ChenL, WangC, LiuH, LiuG, RanX. Antibacterial effect of autologous platelet-rich gel derived from subjects with diabetic dermal ulcers in vitro. J Diabetes Res, 2013; 2013:269527.
10.
JadadAR, MooreRA, CarrollD, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials, 1996; 17:1–12.
11.
OremusM, WolfsonC, PerraultA, DemersL, MomoliF, MorideY. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials. Dement Geriatr Cogn Disord, 2001; 12:232–236.
12.
NguyenNH, SinghS. A primer on systematic reviews and meta-analyses. Semin Liver Dis, 2018; 38:103–111.
13.
HigginsJP, ThompsonSG. Controlling the risk of spurious findings from meta-regression. Stat Med, 2004; 23:1663–1682.
14.
PatsopoulosNA, EvangelouE, IoannidisJP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol, 2008; 37:1148–1157.
15.
EggerM, Davey SmithG, SchneiderM, MinderC. Bias in meta-analysis detected by a simple, graphical test. BMJ, 1997; 315:629–634.
16.
GjerdevikM, HeuchI. Improving the error rates of the Begg and Mazumdar test for publication bias in fixed effects meta-analysis. BMC Med Res Methodol, 2014; 14:109.
17.
WetterslevJ, ThorlundK, BrokJ, GluudC. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol, 2008; 61:64–75.
18.
WetterslevJ, ThorlundK, BrokJ, GluudC. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol, 2009; 9:86.
19.
ThorlundK, DevereauxPJ, WetterslevJ, et al.Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?. Int J Epidemiol, 2009; 38:276–286.
20.
WuXD, LiuMM, LiangX, HuN, HuangW. Effects of perioperative supplementation with pro-/synbiotics on clinical outcomes in surgical patients: a meta-analysis with trial sequential analysis of randomized controlled trials. Clin Nutr, 2018; 37:505–515.
21.
BarrattA, WyerPC, HatalaR, et al.; Evidence-Based Medicine Teaching Tips Working Group. Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ, 2004; 171:353–358.
22.
DriverVR. A prospective, randomized, controlled, blinded, multicenter pivotal trial of a platelet rich plasma gel* versus control when added to the standard of care in the treatment of non-healing diabetic foot ulcers. Diabetes, 2006; 55(Suppl 1):A25.
23.
AhmedM, ReffatSA, HassanA, EskanderF. Platelet-rich plasma for the treatment of clean diabetic foot ulcers. Ann Vasc Surg, 2017; 38:206–211.
24.
LiL, ChenD, WangC, et al.Autologous platelet-rich gel for treatment of diabetic chronic refractory cutaneous ulcers: a prospective, randomized clinical trial. Wound Repair Regen, 2015; 23:495–505.
25.
HollowayGA, SteedDL, DemarcoMJ, Moosa. A randomized, controlled dose response trial of activated platelet supernatant, topical CT-102 in chronic, nonhealing diabetic wounds. Wounds, 1993; 5:198–206.
26.
SteedDL, GoslenJB, HollowayGA, MaloneJM, BuntTJ, WebsterMW. Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo. Diabetes Care, 1992; 15:1598–1604.
27.
SteedDL, EdingtonHD, WebsterMW. Recurrence rate of diabetic neurotrophic foot ulcers healed using topical application of growth factors released from platelets. Wound Repair Regen, 1996; 4:230–233.
28.
SaldalamacchiaG, LapiceE, CuomoV, et al.A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers. Nutr Metab Cardiovas Dis, 2004; 14:395–396.
29.
FrieseG, HertenM, ScherbaumWA. The use of autologous platelet concentrate activated by autologous thrombin (APC+) is effective and safe in the treatment of chronic diabetic foot ulcers: a randomized controlled trial. Fifth International Symposium Diabetic Foot Noordwijkerhout, The Netherlands2007.
30.
VillelaDL, SantosV. Evidence on the use of platelet-rich plasma for diabetic ulcer: a systematic review. Growth Factors, 2010; 28:111–116.
31.
PicardF, HersantB, BoscR, MeningaudJP. The growing evidence for the use of platelet-rich plasma on diabetic chronic wounds: a review and a proposal for a new standard care. Wound Repair Regen, 2015; 23:638–643.
32.
Martinez-ZapataMJ, Martí-CarvajalAJ, SolàI, et al.Autologous platelet-rich plasma for treating chronic wounds. Cochrane Database Syst Rev, 2016;(5):CD006899. doi:10.1002/14651858.CD006899.pub3.
33.
LiL, WangC, WangY, et al.[Impact of topical application of autologous platelet-rich gel on medical expenditure and length of stay in hospitals in diabetic patients with refractory cutaneous ulcers]. Sichuan Da Xue Xue Bao Yi Xue Ban, 2012; 43:762–765.
34.
Martinez-ZapataMJ, Martí-CarvajalAJ, SolàI, et al.Autologous platelet-rich plasma for treating chronic wounds. Cochrane Database Syst Rev, 2012; 10:CD006899. doi: 10.1002/14651858.CD006899.pub2.
35.
ChoJW, KimSA, LeeKS. Platelet-rich plasma induces increased expression of G1 cell cycle regulators, type I collagen, and matrix metalloproteinase-1 in human skin fibroblasts. Int J Mol Med, 2012; 29:32–36.
36.
PietramaggioriG, SchererSS, MathewsJC, et al.Quiescent platelets stimulate angiogenesis and diabetic wound repair. J Surg Res, 2010; 160:169–177.
37.
DeRossiR, CoelhoAC, MelloGS, et al.Effects of platelet-rich plasma gel on skin healing in surgical wound in horses. Acta Cir Bras, 2009; 24:276–281.
38.
PortaN, BonetC, CoboE. Discordance between reported intention-to-treat and per protocol analyses. J Clin Epidemiol, 2007; 60:663–669.
